Hepatosplenic T cell lymphoma in inflammatory bowel disease

Gut

Volumn 57, Issue 12, 2008, Pages 1639-1641

  Shale, Matthew ^a   Kanter, Ed ^a   Panaccione, Remo ^b   Ghosh, Subrata ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ANTIBODY; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANKYLOSING SPONDYLITIS; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RISK; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FOOD AND DRUG ADMINISTRATION; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE RHEUMATOID ARTHRITIS; MONOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SHORT SURVEY; STEM CELL TRANSPLANTATION; T CELL LYMPHOMA; ULCERATIVE COLITIS;

HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LIVER NEOPLASMS; LYMPHOMA, T-CELL; SPLENIC NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 56549085510     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.163279     Document Type: Short Survey

References (29)

1. Beaugerie L, Carrat F, Bouvier A-M, et al. Excess risk of lymphoproliferative disorders (LPD) in inflammatory bowel diseases (IBD): interim results of the CESAME cohort. Gastroenterology 2008;134(Suppl 1):A116-7.
2. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5.
3. Bernstein C, Blanchard J, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91:854-62.
4. Palli D, Trallori G, Bagnoli S, et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology 2000;119:647-53.
5. Lewis J, Schwartz S, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000;118:1018-24.
6. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007;56:1226-31.
7. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008;134:1861-8.
8. Feagan BG, McDonald J, Ponich T, et al. A randomized trial of methotrexate (MTX) in combination with infliximab (IFX) for the treatment of Crohn's disease (CD). Gastroenterology 2008;134:682c.
9. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929-36.
10. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8.
11. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with anti-TNF agents for the treatment of Crohn's disease: a meta-analysis. Gastroenterology 2008;134(suppl1):A144.
12. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30.
13. Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002;122:72-7.
14. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T-cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7.
15. Belhadj K, Reyes F, Farcet J-P, et al. Hepatosplenic T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003;102:4261-9.
16. Vega F, Medeiros LJ, Gaulard P. Hepatosplenic and other gammadelta T-cell lymphomas. Am J Clin Pathol 2007;127:869-80.
17. Khan WA, Yu L, Eisenbrey AB, et al. Hepatosplenic gamma/delta T-cell lymphoma in immunocompromised patients. Report of two cases and review of literature. Am J Clin Pathol 2001;116:41-50.
18. Au W-Y, Ma ESK, Choy C, et al. Therapy-related lymphomas in patients with autoimmune diseases after treatment with disease-modifying anti-rheumatic drugs. Am J Hematology 2006;81:5-11.
19. Leone G, Pagano L, Ben-Yehuda D, Voso M. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007;92:1389-98.
20. Lemann M, de la Valussiere FG, Bouhnik Y, et al. Intravenous cyclosporine for refractory attacks of Crohn's disease (CD): long-term follow-up of patients. Gastroenterology 1998;114(Suppl 1):A1020.
21. Navarro JT, Ribera JM, Mate JL, et al. Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma 2003;44:531-3.
22. Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005;40:220-2.
23. Rosh JR, Magidson J, Miller M. T-Cell hepatosplenic lymphoma in an adolescent on azathioprine monotherapy for ulcerative colitis and autoimmune hepatitis. NASPGHAN 2006:81 Available at http://www.naspghan.org/PDF/ clinical%20vignette%20posters.pdf (accessed 3 Sep 2008).
24. Mittal S, Milner BJ, Johnston PW, et al. A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab. Eur J Haematol 2006;76:531-4.
25. Keller KM. Hepatosplenic T-cell lymphoma in a 15-year old boy with ulcerative colitis treated with azathioprine for 9 years. J Pediatr Gastroenterol Nutr 2007;44:e259.
26. US Food and Drug Administration. Center for Drug Evaluation and Research Website Available at: http://www.fda.gov/cder/aers/extract.htm (accessed 13 Jul 2008).
27. Jaeger G, Bauer F, Brezinschek R, et al. Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine. Ann Oncol 2008;19:1025-6.
28. Tey SK, Marlton PV, Hawley CM, et al. Post-transplant hepatosplenic T-cell lymphoma successfully treated with HyperCVAD regimen. Am J Hematol 2008;83:330-3.
29. Konuma T, Ooi J, Takahashi S, et al. Allogeneic stem cell transplantation for hepatosplenic gammadelta T-cell lymphoma. Leuk Lymphoma 2007;48:630-2.